Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nls Pharmaceutics Ltd (NLSP)

Nls Pharmaceutics Ltd (NLSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,072
  • Shares Outstanding, K 11,779
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,860 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.83
Trade NLSP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9301 +1.06%
on 01/21/22
2.4000 -60.83%
on 01/04/22
-0.3700 (-28.24%)
since 12/21/21
3-Month
0.9301 +1.06%
on 01/21/22
2.8300 -66.78%
on 11/30/21
-1.4200 (-60.17%)
since 10/21/21

Most Recent Stories

More News
NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar

ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...

NLSP : 0.9400 (-7.84%)
NLSPW : 0.2999 (-7.35%)
NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation

- Key patent now granted in major markets including the U.S., Europe, Canada & South Korea - Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention...

NLSP : 0.9400 (-7.84%)
NLSPW : 0.2999 (-7.35%)
NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model

STANS, SWITZERLAND / ACCESSWIRE / November 30, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...

NLSPW : 0.2999 (-7.35%)
NLSP : 0.9400 (-7.84%)
NLS Pharmaceutics CEO Issues Letter to Shareholders

STANS, SWITZERLAND / ACCESSWIRE / November 1, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSP : 0.9400 (-7.84%)
NLSPW : 0.2999 (-7.35%)
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID

STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...

NLSP : 0.9400 (-7.84%)
NLSPW : 0.2999 (-7.35%)
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be...

CLGN : 10.23 (-11.04%)
NLSP : 0.9400 (-7.84%)
TGCB : 0.7000 (+16.67%)
OSS.VN : 0.440 (-6.38%)
OSSIF : 0.3559 (-5.04%)
MITI : 0.1653 (-3.62%)
AYRO : 1.1800 (-6.35%)
IMAC : 1.3600 (-5.56%)
CR : 99.59 (-1.68%)
MYO : 7.91 (-4.58%)
BASA : 0.1910 (-4.50%)
ADIL : 2.34 (-6.02%)
NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side

STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development...

NLSP : 0.9400 (-7.84%)
NLSPW : 0.2999 (-7.35%)
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment

STANS, SWITZERLAND / ACCESSWIRE / September 28, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...

NLSP : 0.9400 (-7.84%)
NLSPW : 0.2999 (-7.35%)
NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference

STANS, SWITZERLAND / ACCESSWIRE / September 24, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery...

NLSP : 0.9400 (-7.84%)
NLSPW : 0.2999 (-7.35%)
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled

STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery...

NLSP : 0.9400 (-7.84%)
NLSPW : 0.2999 (-7.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

NLS Pharmaceutics Ltd. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of therapies for rare and complex central nervous system disorders. The company's principal product candidate includes Quilience(R). NLS Pharmaceutics Ltd. is based in Switzerland.

See More

Key Turning Points

3rd Resistance Point 1.1199
2nd Resistance Point 1.0799
1st Resistance Point 1.0100
Last Price 0.9400
1st Support Level 0.9001
2nd Support Level 0.8601
3rd Support Level 0.7902

See More

52-Week High 7.3500
Fibonacci 61.8% 4.8976
Fibonacci 50% 4.1400
Fibonacci 38.2% 3.3825
Last Price 0.9400
52-Week Low 0.9301

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar